2022
Impact of Frailty on Morbidity and Mortality in Adult Patients Undergoing Surgical Evacuation of Acute Traumatic Subdural Hematoma
Elsamadicy AA, Sandhu MRS, Freedman IG, Koo AB, Reeves BC, Yu J, Hengartner A, Havlik J, Hong CS, Rutherford HJV, Kim JA, Gerrard J, Gilmore EJ, Omay SB. Impact of Frailty on Morbidity and Mortality in Adult Patients Undergoing Surgical Evacuation of Acute Traumatic Subdural Hematoma. World Neurosurgery 2022, 162: e251-e263. PMID: 35276399, DOI: 10.1016/j.wneu.2022.02.122.Peer-Reviewed Original ResearchMeSH KeywordsAdultFrailtyHematoma, SubduralHematoma, Subdural, AcuteHematoma, Subdural, IntracranialHumansMorbidityPostoperative ComplicationsRetrospective StudiesConceptsAcute traumatic subdural hematomaTraumatic subdural hematomaHospital mortalityNonroutine dischargeSubdural hematomaExtended LOSIndependent predictorsAdult patientsBaseline frailtyMultivariate logistic regression analysisExtended hospital lengthImpact of frailtyRetrospective cohort studyNational Trauma DatabaseLogistic regression analysisRegression analysisMultivariate regression analysisHealth care expendituresFrail patientsHospital lengthCohort studySurgical evacuationFrailty indexTrauma databasePatientsChanges in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.Peer-Reviewed Original ResearchConceptsProstate cancer screeningUS Preventive Services Task ForcePSA testingCancer screeningInterrupted time series analysisCohort studyUS Preventive Services Task Force (USPSTF) recommendationDraft statementLarge national cohort studyEligible beneficiariesPSA testing ratesRetrospective cohort studyRate of PSANational cohort studyProstate-specific antigenAge-adjusted ratesTask Force recommendationsUSPSTF guidelinesMedian ageGuideline changesProstate cancerMedian numberMAIN OUTCOMEClaims dataTesting rates
2021
Emergency department visits for radiation cystitis among patients with a prostate cancer history
Lee V, An Y, Park HS, Yu JB, Kim SP, Jairam V. Emergency department visits for radiation cystitis among patients with a prostate cancer history. BJU International 2021, 130: 208-216. PMID: 34806813, DOI: 10.1111/bju.15650.Peer-Reviewed Original ResearchMeSH KeywordsCystitisEmergency Service, HospitalHumansMaleProstateProstatic NeoplasmsRetrospective StudiesUrinary RetentionConceptsProstate cancer historyRadiation cystitisED visitsInvasive proceduresCancer historyProstate cancerRadiation therapyHigher median total chargesNationwide Emergency Department SampleEmergency department visitsEmergency Department SampleMedian total chargesPrior prostatectomyUrinary retentionBlood transfusionDepartment visitsMedian lengthEmergency departmentNational burdenSecondary diagnosisPrimary diagnosisHospital characteristicsPotential complicationsEffective modalityInvasive measuresAdoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingHospital referral regionsProportion of patientsProstate cancerGenomic testingCohort studyReferral regionsRetrospective cohort studyProstate cancer carePatient-level analysisCommercial insurance claimsProstate cancer managementUS hospital referral regionsYears of ageProportion of menPatients 40Definitive treatmentCancer careTesting uptakeHRR levelMAIN OUTCOMECancer managementPatientsRegional uptakeIncidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis
Sandhu MRS, Chiang VL, Tran T, Yu JB, Weiss S, Goldberg S, Aboian M, Kluger HM, Mahajan A. Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. Journal Of Neuro-Oncology 2021, 154: 197-203. PMID: 34351544, DOI: 10.1007/s11060-021-03813-8.Peer-Reviewed Original ResearchMeSH KeywordsBrain NeoplasmsHumansIncidenceMaleMelanomaPrognosisRetrospective StudiesTesticular NeoplasmsConceptsStage IV melanomaMetastatic brain lesionsStage IIIInitial diagnosisTumor RegistryOverall incidenceBrain lesionsBM incidenceSingle-institute retrospective analysisBM developmentBrain metastases incidenceIncidence of BMInstitution's tumor registryStage III patientsTime of diagnosisMetastatic intracranial lesionsCommon genetic mutationsTumor genetic profileGenetic profileBM occurrenceMedian durationAdvanced melanomaSurveillance regimenIII patientsMedian timePrevalence of Missing Data in the National Cancer Database and Association With Overall Survival
Yang DX, Khera R, Miccio JA, Jairam V, Chang E, Yu JB, Park HS, Krumholz HM, Aneja S. Prevalence of Missing Data in the National Cancer Database and Association With Overall Survival. JAMA Network Open 2021, 4: e211793. PMID: 33755165, PMCID: PMC7988369, DOI: 10.1001/jamanetworkopen.2021.1793.Peer-Reviewed Original ResearchMeSH KeywordsAgedData ManagementDatabases, FactualFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasmsPrevalenceRegistriesRetrospective StudiesSurvival RateUnited StatesConceptsNational Cancer DatabaseNon-small cell lung cancerOverall survivalCell lung cancerCancer DatabaseMedical recordsLung cancerProstate cancerBreast cancerPatient recordsComplete dataRetrospective cohort studyCohort studyCancer RegistryCommon cancerVariables of interestHigh prevalenceMAIN OUTCOMEPatientsClinical advancementReal-world data sourcesCancerPrevalenceSurvivalHeterogeneous differences
2020
Physician trajectories of abandoning long‐course breast radiotherapy and their cost impact
Xu X, Soulos PR, Herrin J, Wang S, Pollack CE, Evans SB, Yu JB, Gross CP. Physician trajectories of abandoning long‐course breast radiotherapy and their cost impact. Health Services Research 2020, 56: 497-506. PMID: 33070305, PMCID: PMC8143683, DOI: 10.1111/1475-6773.13572.Peer-Reviewed Original ResearchConceptsPhysician peer groupsWhole breast irradiationCF-WBIRisk-adjusted ratesBreast radiotherapyPractice patternsLow useChronic Conditions Data WarehouseDistinct practice patternsPatients' clinical characteristicsSetting of radiotherapyAdjuvant breast radiotherapyYears of ageDistinct trajectoriesImportant cost implicationsHigher useAdjuvant radiotherapyClinical characteristicsEligible womenBreast cancerCost implicationsLatent class growth analysisService beneficiariesMedicare programRadiotherapyNational Patterns in Prescription Opioid Use and Misuse Among Cancer Survivors in the United States
Jairam V, Yang DX, Verma V, Yu JB, Park HS. National Patterns in Prescription Opioid Use and Misuse Among Cancer Survivors in the United States. JAMA Network Open 2020, 3: e2013605. PMID: 32804217, PMCID: PMC7431994, DOI: 10.1001/jamanetworkopen.2020.13605.Peer-Reviewed Original ResearchConceptsPrescription opioid usePrescription opioid misuseRecent cancer survivorsOpioid useCancer survivorsAdult cancer survivorsOpioid misuseUse disordersHigher prescription opioid useRecent cancer historyCancer-related painHistory of cancerPopulation-based studyNonmelanoma skin cancerDrug use disordersCross-sectional studyAlcohol use disorderLong-term misusePrescription opioidsCancer historyMAIN OUTCOMESkin cancerDrug useYounger ageCancerEvaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases
Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T, Yomo S, Aiyama H, Higuchi Y, Shuto T, Akabane A, Sato Y, Niranjan A, Faramand AM, Lunsford LD, McInerney J, Tuanquin LC, Zacharia BE, Chiang V, Singh C, Yu JB, Braunstein S, Mathieu D, Touchette CJ, Lee CC, Yang HC, Aizer AA, Cagney DN, Chan MD, Kondziolka D, Bernstein K, Silverman JS, Grills IS, Siddiqui ZA, Yuan JC, Sheehan JP, Cordeiro D, Nosaki K, Seto T, Deibert CP, Verma V, Day S, Halasz LM, Warnick RE, Trifiletti DM, Palmer JD, Attia A, Li B, Cifarelli CP, Brown PD, Vargo JA, Combs SE, Kessel KA, Rieken S, Patel S, Guckenberger M, Andratschke N, Kavanagh BD, Robin TP. Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. JAMA Oncology 2020, 6: 1028-1037. PMID: 32496550, PMCID: PMC7273318, DOI: 10.1001/jamaoncol.2020.1271.Peer-Reviewed Original ResearchMeSH KeywordsAgedBrain NeoplasmsCranial IrradiationFemaleHumansLung NeoplasmsMaleMiddle AgedRadiosurgeryRetrospective StudiesSmall Cell Lung CarcinomaConceptsWhole brain radiotherapyProgression-free survivalSmall-cell lung cancer (SCLC) brain metastasesCell lung cancer brain metastasesCNS progression-free survivalLung cancer brain metastasesPropensity score-matched analysisMedian overall survivalCancer brain metastasesBrain metastasesOverall survivalStereotactic radiosurgeryCentral nervous system (CNS) progression-free survivalMedian CNS progression-free survivalSRS outcomesCentral nervous system progressionSmall cell lung cancerLimited brain metastasesMulticenter cohort studyDisease control statusCell lung cancerSingle-arm trialStandard of careLeptomeningeal progressionWBRT cohortNational trends in the management of patients with positive surgical margins at radical prostatectomy
Ghabili K, Park HS, Yu JB, Sprenkle PC, Kim SP, Nguyen KA, Ma X, Gross CP, Leapman MS. National trends in the management of patients with positive surgical margins at radical prostatectomy. World Journal Of Urology 2020, 39: 1141-1151. PMID: 32562045, DOI: 10.1007/s00345-020-03298-6.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyPositive surgical marginsUse of ADTPost-prostatectomy radiation therapyRadiation therapySurgical marginsRadical prostatectomyInitial courseNode-negative prostate cancerPost-operative radiation therapyMultivariable logistic regression modelNational Cancer DatabaseAdverse pathologic featuresManagement of patientsPost-operative managementLogistic regression modelsDeprivation therapySurgical cancersPrimary endpointRT useSecondary endpointsPathologic characteristicsPathologic featuresUninsured statusCancer DatabaseDefining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, Méndez Romero A, Nevens D, Palma D, Park C, Ricardi U, Scorsetti M, Yu J, Woodward W. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy And Oncology 2020, 148: 157-166. PMID: 32388150, DOI: 10.1016/j.radonc.2020.04.003.Peer-Reviewed Original ResearchMeSH KeywordsConsensusDiagnostic ImagingHumansNeoplasm MetastasisNeoplasmsRadiation OncologyRetrospective StudiesConceptsMetastasis-directed radiotherapyDefinition of oligometastatic diseaseOligometastatic diseaseMetastatic sitesAbsence of clinical dataMetachronous oligometastatic diseaseRadiation oncology perspectiveDisease-free intervalSingle-centre seriesContext of radiotherapyPatient inclusion criteriaProgression-freeMetastatic locationsCurative intentMetastatic lesionsOverall survivalPrimary tumorSystemic therapyOncological perspectiveQuality-of-lifeClinical dataRadiotherapyLocal controlConsensus documentInclusion criteriaBeyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto W, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, Yu J, Chiang V, Nakano T, Aoyama H, Mehta MP. Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. International Journal Of Radiation Oncology • Biology • Physics 2020, 107: 334-343. PMID: 32084525, PMCID: PMC7276246, DOI: 10.1016/j.ijrobp.2020.01.051.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrain NeoplasmsBRCA1 ProteinBreast NeoplasmsFemaleHumansMiddle AgedPrognosisRetrospective StudiesSurvival AnalysisConceptsDiagnosis-specific prognostic factorsHuman epidermal receptor 2Prognostic factorsMedian survivalBreast-GPABrain metastasesBreast cancerCohort BCohort APrognostic indexReceptor 2Tumor subtypesBreast cancer brain metastasesKaplan-Meier survival estimatesCancer brain metastasesGraded Prognostic AssessmentKarnofsky performance statusLarge contemporary cohortLog-rank testFuture clinical trialsNew prognostic factorsGPA 0Extracranial metastasesPerformance statusBetter prognosisEstrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto W, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, Yu J, Chiang V, Nakano T, Aoyama H, Mehta MP. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro-Oncology 2020, 22: 1359-1367. PMID: 32034917, PMCID: PMC7523450, DOI: 10.1093/neuonc/noaa025.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBrain NeoplasmsBreast NeoplasmsEstrogensHumansReceptor, ErbB-2Receptors, ProgesteroneRetrospective StudiesConceptsBreast cancer brain metastasesHuman epidermal growth factor receptor 2Primary tumorProgesterone receptorMedian survivalEstrogen receptorBrain metastasesDiscordance rateHER2-negative primary tumorsEstrogen/progesterone receptorsEpidermal growth factor receptor 2Time of metastasisCancer brain metastasesGrowth factor receptor 2Breast cancer treatmentIncidence of discordanceFactor receptor 2Subsequent treatmentBCBM patientsHER2 discordanceReceptor discordanceMost patientsReceptor statusInitial diagnosisHER2 status
2019
Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database
Mahal A, Butler S, Franco I, Muralidhar V, Larios D, Pike L, Zhao S, Sanford N, Dess R, Feng F, D’Amico A, Spratt D, Yu J, Nguyen P, Rebbeck T, Mahal B. Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer 2019, 125: 3338-3346. PMID: 31251398, DOI: 10.1002/cncr.32332.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerPositive biopsy coresShort-term outcomesBiopsy coresProstate cancerManagement of low-risk prostate cancerOlder patientsProstate cancer-specific mortality ratesConservative managementProstate cancer-specific mortalityCancer-specific mortality ratesActive surveillance/watchful waitingRate of conservative managementOlder menCancer-specific mortalityShort-term safetyQuality-of-life implicationsDefinitive treatmentYounger patientsOverall mortalityPatientsMortality rateProstateNational databaseCancerUnderutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer
Wang C, Raldow A, Nickols N, Nguyen P, Spratt D, Dess R, Yu J, King C, Chu F, Chamie K, Litwin M, Saigal C, Reiter R, Liu S, Rettig M, Chang A, Steinberg M, Kupelian P, Kishan A. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. European Urology Oncology 2019, 4: 327-330. PMID: 31411981, DOI: 10.1016/j.euo.2019.01.006.Peer-Reviewed Original ResearchMeSH KeywordsAgedAndrogen AntagonistsAndrogensHumansMaleMedicareProstatic NeoplasmsRetrospective StudiesUnited StatesConceptsConcomitant androgen deprivation therapyAndrogen deprivation therapyExternal beam radiotherapyDefinitive external beam radiotherapyHigh-grade prostate cancerGleason grade groupProstate cancerBeam radiotherapyDeprivation therapyGG 4NHW menDuration of androgen deprivation therapyAA menPopulation-based retrospective studyProstate cancer patientsMultiple randomized trialsNon-HispanicInverse probability treatmentSurvival benefitNon-Hispanic white menRetrospective studyRandomized trialsGrade groupRadiotherapyProbability treatment
2018
Medicare Cancer Screening in the Context of Clinical Guidelines
Maroongroge S, Yu J. Medicare Cancer Screening in the Context of Clinical Guidelines. American Journal Of Clinical Oncology 2018, 41: 339-347. PMID: 26886947, DOI: 10.1097/coc.0000000000000272.Peer-Reviewed Original ResearchConceptsCancer screeningScreening ratesFee-for-serviceColorectal cancer screening ratesBilling codesCancer screening ratesColorectal screening testsMedicare fee-for-serviceMedicare Part B beneficiariesMonte Carlo permutation methodMedicare FFS populationBeneficiaries per yearMedicare FFS programEvidence-based guidelinesScreening testRetrospective claims dataProstate cancer screeningPublic health issueMammography ratesFFS populationScreening trendsMedicare populationClaims dataGuideline publicationPatient preferences